Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab plus chemotherapy followed by radiotherapy for first-line oligometastatic esophageal cancer
ChiCTR2300071203Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, cisplatin and paclitaxel in esophageal cancer, sponsored by Shandong Cancer Hospital. Primary endpoint: progression-free survival. Started Mar 2021; status: recruiting.
02
Drugs
sintilimabcisplatinpaclitaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2300071203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071203.